

# Endocrine Abstracts

May 2016 Volume 41  
ISSN 1479-6848 (online)

18th European Congress of  
Endocrinology 2016

28–31 May 2016, Munich, Germany



published by  
**bioscientifica**

Online version available at  
[www.endocrine-abstracts.org](http://www.endocrine-abstracts.org)



## 18th European Congress of Endocrinology

28–31 May 2016

### EDITORS

The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee

#### Programme Organising Committee (POC)

Ipo Huhtaniemi (Finland/UK) Chair, Programme Organising Committee (POC)  
Robin Peeters (The Netherlands) Co-chair, Programme Organising Committee (POC)  
Ewa Rajpert-de Meys (Denmark) Co-chair, Programme Organising Committee (POC)  
Günter Stalla (Germany)

Laura Fugazzolla (Italy)  
Tsvetalina Tankova (Bulgaria)  
William Rainey (USA)  
Constantine Stratakis (USA)  
Sebastian Schmid (Germany)  
Geert Carmeliet (Belgium)  
Christina Kanaka-Gantenbein (Greece)

Nadine Binart (France)  
Filip Gabalec (Czech Republic)  
Bulent Yildiz (Turkey)  
Marjia Pfeifer (Slovenia)  
Jerome Bertherat (France)

#### Local Organising Committee (LOC)

Gunter Stalla (Germany)  
Christoph Auernhammer (Germany)  
Felix Beuschlein (Germany)  
Michael Buchfelder (Germany)  
Helmuth GüntherDörr (Germany)

Jörg Gromoll (Germany)  
Martin Grüssendorf (Germany)  
Martin Reincke (Germany)  
Vanadin Seifert-Klauss (Germany)  
Christine Spitzweg (Germany)

Marily Theodoropoulou (Germany)  
Matthias Tschöp (Germany)  
Günter Höfle (Austria)  
Emanuel Christ (Switzerland)

#### Abstract Marking Panel

J Achermann UK  
M Alevizaki Greece  
G Assié France  
S Aylwin UK  
S Babajko France  
K Badenhop Germany  
D Bassett UK  
E Baudin France  
A Beckers Belgium  
P Beck-Peccoz Italy  
J Bertherat France  
F Beuschlein Germany  
B Bilinska Poland  
M Blucher Germany  
K Boelaert UK  
A Boelen The Netherlands  
R Bouillon Belgium  
J-P Bourguignon Belgium  
G Brabant Germany  
M L Brandi Italy  
K Briot France  
G Brunetti Italy  
C Buchanan UK  
S Cannavo Italy  
J Cap Czech Republic  
JS Carroll UK  
J Castano Spain  
P Chanson France  
K Chatterjee UK  
I Chiodini Italy  
J Chowen Spain  
T Coll UK  
D Cuthbertson UK  
K Dahlman-Wright Sweden  
C Daousi UK  
M Dattani UK  
C Dayan UK  
W de Herder Netherlands  
E de Koning The Netherlands  
B Demeneix France  
M Dentice Italy  
W Dhillon UK  
G Di Dalmazi Germany  
E Diamanti-Kandarakis Greece  
F Dotto Italy  
J Drouin Canada  
L Duntas Greece  
G Eisenhofer Germany  
F Fallo Italy  
P Farahani Canada  
S Farooqi UK

M Fassnacht Germany  
R Feelders The Netherlands  
U Feldt-Rasmussen Denmark  
F Flamant France  
E Fliers The Netherlands  
C Fluck Germany  
C Follin Sweden  
S Franks UK  
W Fraser UK  
J Frystyk Denmark  
L Fugazzolla Italy  
D Fuhrer Germany  
F Gabalec Czech Republic  
R Gärtner Germany  
A-P Gimenez-Roqueplo France  
F Giorgino Italy  
J Gomez-Ambrosi Spain  
R Granata Italy  
J Gromoll Germany  
A Grossman UK  
S Hahner Germany  
R Hampl Czech republic  
M Heikinheimo Finland  
S Herzig Germany  
M Hewison UK  
M Hewison UK  
A Hoellich Germany  
C Hofig Sweden  
L Hofland Netherlands  
W Hogler UK  
I Huhtaniemi UK  
P Igaz Hungary  
Erica Isenovic Serbia  
M-L Jaffrain-Rea Italy  
B Jarzab Poland  
C Jazdzewski Poland  
D Jezova Slovakia  
A Juul Denmark  
A Kalsbeek Netherlands  
G Kaltsas Greece  
C Kanaka-Gantenbein Greece  
M Keil USA  
F Kelestimir Turkey  
R Kineman USA  
M Korbonits UK  
N Krone UK  
M Krsek Czech Rep  
H Krude Germany  
M Laan Germany  
M Laan Switzerland  
P Lakatos Hungary

E Lalli  
J Laven The Netherlands  
G Lavery UK  
S Lebouleux France  
J Leger France  
T Links The Netherlands  
S Llahana UK  
A Luger Austria  
RM Luque Spain  
M Luster Germany  
M Maggi Italy  
M Mannelli Italy  
F Mantero Italy  
G Mastorakis Greece  
E Mathiesen Denmark  
C McCabe UK  
R Mitchell UK  
J Mittag Germany  
L Morin-Papunen Finland  
N Morton UK  
A Mukherjee UK  
E Nagy Hungary  
J Newell-Prize UK  
D O'Halloran Ireland  
U Pagotto Italy  
JJ Palvimo Finland  
S Papopolous Netherlands  
S Pearce UK  
R Peeters The Netherlands  
L Persani Italy  
M Pfeifer Slovenia  
T Pieber Austria  
N Pitteloud Switzerland  
M Poutanen Finland  
D Power Portugal  
V Prevot France  
S Radian UK  
N Rahman Finland  
B Rainey USA  
T Raiivo Finland  
E Rajpert-De Meys Denmark  
G Raverot France  
M Reincke Germany  
S Rice UK  
I Robert UK  
M Robledo Spain  
P Rodien France  
G Roman Romania  
H Romijn The Netherlands  
C Ronchi Italy  
R Ross UK

GP Rossi  
M Ruchala Poland  
E Rutten Belgium  
S Sanlioglu Turkey  
P Saunders UK  
S Schmid Germany  
P Schöffski Belgium  
J Schopohl Germany  
M Schott Germany  
U Smith Sweden  
A Spada  
G Stalla Germany  
E Stener-Victorin Sweden  
C Stratakis USA  
T Tankova Bulgaria  
M Tena-Sempere  
M Terzolo  
M Theodoropoulou Germany  
P Thompson UK  
C Thompson Ireland  
V Tillmann Estonia  
H Timmers The Netherlands  
J Toppari Finland  
M Toth Hungary  
S Tsagarakis Greece  
M Tzanela Greece  
E Valassi Spain  
E van den Akker Netherlands  
J van der Eck The Netherlands  
AJ van der Lelij Netherlands  
W van Hul Belgium  
H van Leeuwen The Netherlands  
B Verges France  
E Visser The Netherlands  
J Visser The Netherlands  
P Vitti Italy  
V Volke Estonia  
Tracy Williams Italy  
T Williams UK  
Z Wu Germany  
P Yeoh UK  
J Young France  
M Zatelli Italy  
M-C Zennaro France

## SPONSORS

The ESE would like to thank its Corporate Members and the ECE 2016 sponsors

### ECE Corporate Members

- Chiasma
- Eli Lilly
- Ipsen
- Laboratoire HRA Pharma
- Merck Serono
- Novartis Pharmaceuticals
- Novo Nordisk
- Pfizer
- Sandoz International GmbH
- Shire Services BVBA
- Strongbridge Biopharma

### Gold Sponsors

Ipsen  
Novartis

### Bronze Sponsors

Pfizer



#### ESE Office

Euro House  
22 Apex Court  
Woodlands  
Bradley Stoke  
Bristol BS32 4JT, UK

Contact:  
Tel:  
Fax:  
E-mail:  
Web site:

Andrea Davis  
+44 (0)1454 642247  
+44 (0)1454 642222  
info@euro-endo.org  
www.es-hormones.org



#### ECE 2016 Secretariat

Bioscientifica Ltd  
Euro House, 22 Apex Court  
Woodlands  
Bradley Stoke  
Bristol BS32 4JT, UK

Contact:  
Tel:  
Fax:  
E-mail:  
Website:

Niki Cripps  
+44 (0)1454 640467  
+44 (0)1454 642222  
ece2016@bioscientifica.com  
http://www.bioscientifica.com

## CONTENTS

### 18th European Congress of Endocrinology 2016

#### PRIZE LECTURES AND BIOGRAPHICAL NOTES

The European Journal of Endocrinology Prize Lecture . . . . .	EJE1
The Geoffrey Harris Prize Lecture . . . . .	GH1
Clinical Endocrinology Trust Award & Lecture . . . . .	CETL1

#### PLENARY LECTURES

PRRT, NETTER-1, and the new Era . . . . .	PL1
Endocrine disruptors and the thyroid ( <i>Endorsed by Endocrine Connections</i> ) . . . . .	PL2
Testosterone trials . . . . .	PL3
Gut microbiota, inflammation and metabolism ( <i>Endorsed by Endocrine Connections</i> ) . . . . .	PL4
Insulin signalling and action . . . . .	PL5
Bionic pancreas . . . . .	PL6

#### SYMPOSIA

Thyroid and Pregnancy . . . . .	S1.1–S1.3
Mixtures, medicines and diet, where now for endocrine disrupting compounds? ( <i>Endorsed by Endocrine Connections</i> ) . . . . .	S2.1–S2.3
Senescence and plasticity in the anterior pituitary . . . . .	S3.1–S3.3
How to diagnose endocrine disease in obese patients? ( <i>Endorsed by the European Journal of Endocrinology</i> ) . . . . .	S4.1–S4.3
Adrenal incidentaloma guidelines . . . . .	S5.1–S5.7
Characterization and treatment of thyroid cancer . . . . .	S6.1–S6.3
The chronic syndromes of patients with cured pituitary diseases ( <i>Endorsed by the European Journal of Endocrinology</i> ) . . . . .	S7.1–S7.3
Primary aldosteronism . . . . .	S8.1–S8.3
Bone marrow adipose tissue - A "novel" functionally active fat depot . . . . .	S9.1–S9.3
Late Breaking News Session . . . . .	S10.1–S10.3
New Developments in subclinical thyroid disease . . . . .	S11.1–S11.3
Novel insights of disorders in pubertal timing . . . . .	S12.1–S12.3
Management of Cushing's syndrome . . . . .	S13.1–S13.3
Hot topics on vitamin D . . . . .	S14.1–S14.3
In the rhythm of EYES: Let's dance! . . . . .	S15.1–S15.3
Thyroid nodules . . . . .	S16.1–S16.3
Genetics and epigenetics of testicular failure . . . . .	S17.1–S17.3
Neuroendocrine tumours: new findings, classification and targeted management . . . . .	S18.1–S18.3
Brown adipose tissue - a burning issue ( <i>Endorsed by Endocrine Connections</i> ) . . . . .	S19.1–S19.3
Hitchhiker's guide to the microcosmos of GPCRs . . . . .	S20.1–S20.3
An update on hyperparathyroidism . . . . .	S21.1–S21.3
New mechanisms to induce and protect from ovarian insufficiency . . . . .	S22.1–S22.3
Indications of incretin based therapies . . . . .	S23.1–S23.3
Endocrine neoplasias: new associations ( <i>Endorsed by the European Journal of Endocrinology</i> ) . . . . .	S24.1–S24.3
What's new and exciting in nuclear receptor action? . . . . .	S25.1–S25.3
An update on bone homeostasis and osteoporosis ( <i>Endorsed by the European Journal of Endocrinology</i> ) . . . . .	S26.1–S26.3
Why do we gain weight; homeostasis and rewards of ingestive behaviour . . . . .	S27.1–S27.3
Adrenal Insufficiency: Causes and management . . . . .	S28.1–S28.3
New insights into the pathogenesis of PCOS . . . . .	S29.1–S29.3
Disorders of development and function of neurohypophysis . . . . .	S30.1–S30.3

**NEW SCIENTIFIC APPROACHES** . . . . . NSA1–NSA5

**DEBATE**

The use of NSAIDs in endocrine cancers: the case of Celecoxib . . . . . D1.1–D1.3  
 Should we treat subclinical Cushing’s syndrome? . . . . . D2.1–D2.2  
 Strengths and weaknesses of hormone immunoassays and mass spectrometry: what the clinician should know D3.1–D3.2  
 Are we ready for pharmacological therapy of obesity? . . . . . D4.1–D4.2

**MEET THE EXPERT SESSIONS** . . . . . MTE1–MTE10

**ORAL COMMUNICATIONS**

Adrenal - Basic & Clinical . . . . . OC1.1–OC1.5  
 Receptors & Signalling . . . . . OC2.1–OC2.5  
 Diabetes prediction & complications . . . . . OC3.1–OC3.5  
 Thyroid - Clinical . . . . . OC4.1–OC4.5  
 Neuroendocrinology . . . . . OC5.1–OC5.5  
 Diabetes therapy & complications . . . . . OC6.1–OC6.5  
 Cardiovascular endocrinology . . . . . OC7.1–OC7.5  
 Thyroid - Translational . . . . . OC8.1–OC8.5  
 Endocrine Tumours . . . . . OC9.1–OC9.5  
 Reproduction & Endocrine Disruption . . . . . OC10.1–OC10.5  
 Bone & Calcium Homeostasis . . . . . OC11.1–OC11.5  
 Obesity . . . . . OC12.1–OC12.5  
 Pituitary Clinical . . . . . OC13.1–OC13.5  
 Thyroid Cancer . . . . . OC14.1–OC14.5

**GUIDED POSTERS**

Adrenal . . . . . GP1–GP10  
 Adrenal . . . . . GP11–GP20  
 Adrenal . . . . . GP21–GP30  
 Bone & Calcium Homeostasis . . . . . GP31–GP40  
 Bone & Calcium Homeostasis . . . . . GP41–GP50  
 Cardiovascular endocrinology . . . . . GP51–GP59  
 Clinical Case Reports . . . . . GP60–GP69  
 Diabetes . . . . . GP70–GP79  
 Diabetes . . . . . GP80–GP89  
 Diabetes . . . . . GP90–GP99  
 Endocrine Nursing . . . . . GP100–GP108  
 Endocrine Tumours . . . . . GP109–GP118  
 Neuroendocrinology . . . . . GP119–GP128  
 Obesity . . . . . GP129–GP138  
 Paediatric Endocrinology & Development . . . . . GP139–GP148  
 Pituitary - Clinical . . . . . GP149–GP158  
 Pituitary - Clinical . . . . . GP159–GP168  
 Receptors & Signalling . . . . . GP169–GP178  
 Reproduction & Endocrine Disruption . . . . . GP179–GP188  
 Thyroid - Basic . . . . . GP189–GP198  
 Thyroid - Translational & Clinical . . . . . GP199–GP208  
 Thyroid - Translational & Clinical . . . . . GP209–GP218  
 Thyroid Cancer . . . . . GP219–GP228  
 Thyroid Cancer . . . . . GP229–GP238

**EPOSTER PRESENTATIONS**

Adrenal cortex (to include Cushing’s) . . . . . EP1–EP83  
 Adrenal medulla . . . . . EP84–EP96  
 Bone & Osteoporosis . . . . . EP97–EP134  
 Calcium and Vitamin D metabolism . . . . . EP135–EP194  
 Cardiovascular Endocrinology and Lipid Metabolism . . . . . EP195–EP245  
 Clinical case reports - Pituitary/Adrenal . . . . . EP246–EP326

Clinical case reports - Thyroid/Others . . . . .	EP327-EP396
Developmental endocrinology . . . . .	EP397-EP400
Diabetes (to include epidemiology, pathophysiology) . . . . .	EP401-EP483
Diabetes complications . . . . .	EP484-EP537
Diabetes therapy . . . . .	EP538-EP581
Endocrine Disruptors . . . . .	EP582-EP587
Endocrine Nursing . . . . .	EP588
Endocrine tumours and neoplasia . . . . .	EP589-EP656
Female Reproduction . . . . .	EP657-EP698
Growth hormone IGF axis - basic . . . . .	EP699-EP709
Male Reproduction . . . . .	EP710-EP727
Neuroendocrinology . . . . .	EP728-EP770
Nuclear receptors and Signal transduction . . . . .	EP771-EP776
Obesity . . . . .	EP777-EP844
Paediatric endocrinology . . . . .	EP845-EP852
Pituitary - Basic . . . . .	EP853-EP869
Pituitary - Clinical . . . . .	EP870-EP952
Steroid metabolism + action . . . . .	EP953-EP965
Thyroid (non-cancer) . . . . .	EP966-EP1085
Thyroid cancer . . . . .	EP1086-EP1166

**INDEX OF AUTHORS**

# Eposter Presentations

significantly lower in hypercalciuric group compared to normocalciuric group and healthy control group ( $P < 0.0001$ ,  $P = 0.005$ ). Serum PTH levels were observed significantly higher in hypercalciuric group compared to normocalciuric group ( $P = 0.03$ ). 24-hour urinary calcium levels showed positive correlation with PTH and serum calcium levels ( $r = -0.37$ ,  $r = 0.47$ ,  $P < 0.0001$ ) and negative correlation with femur neck and lumbar BMD levels in PHPT patients. ( $r = -0.23$ ,  $P = 0.001$ ;  $r = -0.27$ ,  $P = 0.02$ ). Patients whose serum calcium levels were normal or mildly elevated were tested for CGR mutation and it resulted negative.

#### Conclusion

Our study also showed that there is positive correlation between urinary calcium levels and serum PTH levels in newly diagnosed PHPT patients. It also supports the opinion that hypercalciuria could be a marker bone loss in PHPT patients.

DOI: 10.1530/endoabs.41.EP144

## EP145

### Bone mineral density measurement in newly diagnosed primary hyperparathyroidism patients

Bahar Tekin<sup>1</sup>, M. Melin Uygur<sup>2</sup>, F. Buket Bayram<sup>1</sup> & Dilek Gogas Yavuz<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, Marmara University Hospital, Marmara University School of Medicine, Istanbul, Turkey; <sup>2</sup>Department of Internal Medicine, Section of Endocrinology and Metabolism, Marmara University Hospital, Marmara University School of Medicine, Istanbul, Turkey.

#### Aim

Clinical presentation of primary hyperparathyroidism (PHPT) differs between populations. In this study, we aimed to examine bone mineral density (BMD) and bone metabolism parameters in newly diagnosed and untreated PHPT patients in a single endocrine center in Istanbul, Turkey.

#### Methods

Consecutive 256 PHPT patients (50.7 ± 14 years, F/M:205/51) and 89 healthy controls (38.8 ± 10 years, F/M:67/22) were included in the study. Serum calcium, phosphorus, parathyroid hormone (PTH), 25(OH) vitamin D, creatinine, 24-h urinary calcium were measured. DEXA method was used for bone mineral density (BMD) measurement.

#### Results

Twenty percent of PHPT patients were symptomatic and nephrolithiasis was shown in 20.3% of the patients. Serum calcium levels were 11.2 ± 1.3 mg/dl and 9.6 ± 0.3 mg/dl ( $P < 0.0001$ ), serum PTH levels were 273.4 ± 374 pg/ml and 61.3 ± 28 pg/ml ( $P < 0.001$ ) and serum 25OH D levels were 21.9 ± 20.1 ng/ml and 10.4 ± 7.1 ng/ml ( $P < 0.0001$ ) for PHPT and control groups respectively. 24-h urinary calcium levels were 294.4 ± 213.9 mg/day in PHPT group and 137 ± 69.2 mg/day in healthy control group ( $P < 0.0001$ ). Femur neck BMD were 0.82 ± 0.15 g/cm<sup>2</sup> and 0.98 ± 0.14 g/cm<sup>2</sup> ( $P < 0.0001$ ) for PHPT and control groups respectively. Femur neck and lumbar BMDs, T and Z scores were observed significantly lower in PHPT group compared to healthy controls group ( $P < 0.0001$ ). Femur neck and lumbar BMD levels showed negative correlation with PTH in PHPT patients ( $r = -0.37$ ,  $P < 0.0001$ ). There were osteoporosis in 13.4 percent ( $n:34$ ) and osteopenia in 9.9 percent ( $n:25$ ) of PHPT patients.

#### Conclusion

In our group of patients osteoporosis was diagnosed lower than expected but BMD measurements were lower in PHPT group. The results of this study show that bone turnover is increased and bone mineral density is decreased in PHPT patients, as stated in previous studies.

DOI: 10.1530/endoabs.41.EP145

## EP146

### Serum calcium to phosphorus ratio (Ca/P) as a simple, inexpensive screening tool in the diagnosis of primary hyperparathyroidism (PHPT)

Bruno Madeo<sup>1</sup>, Elda Kara<sup>1</sup>, Katia Cioni<sup>1</sup>, Silvia Vezzani<sup>1</sup>, Manuela Simoni<sup>1,2</sup> & Vincenzo Rochira<sup>1,2</sup>

<sup>1</sup>Unit of Endocrinology, Azienda USL of Modena, Modena, Italy; <sup>2</sup>Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

#### Background

PHPT is often overlooked/underdiagnosed. Several strategies (biochemical markers alone or combined in complex algorithms) have been investigated to

easily diagnose/screen PHPT, but PHPT diagnosis remains challenging at present, especially in asymptomatic patients. As serum calcium (Ca) and phosphorus (P) are inversely related in PHPT, the Ca/P ratio could be a good candidate tool for PHPT diagnosis. Surprisingly, no literature data on Ca/P ratio are available, despite they are very simple biochemical measurements largely available in any clinical lab setting.

#### Aim

To investigate the Ca/P ratio diagnostic value in the diagnosis of PHPT.

#### Methods

Data retrospectively obtained from review charts of 97 patients with documented PHPT (69 females; 28 males) [16 (17%) with severe hypercalcemia (> 12 mg/dl); 44 (45%) mild hypercalcemia, 36 (38%) normocalcemic PHPT (NCHPT)] were compared with those of 96 controls (C) (44 females; 52 males). Exclusion criteria: age < 18 years, severe chronic diseases, cancer, bone metabolic diseases, use of medications affecting serum Ca. Biochemical measurements: PTH, Vitamin D, serum Ca, P, albumin, and creatinine. Normal ranges: PTH (15–88 pg/ml), Ca (8.5–11 mg/dl), P (2.5–5.1 mg/dl). SPSS 19.0 and SigmaPlot 11.0 were used for statistics (group comparisons, ROC curves, cutoffs performance).

#### Results

Ca and PTH were significantly higher in PHPT [(Ca median:11; min-max:9.4–15.5); (PTH 135.2; 57.6–1748)] than C [(Ca 9.4; 8.3–10.2); (PTH 32.1; 14–106.1)] ( $P < 0.0001$ ). P was significantly lower in PHPT (2.4; 1.4–3.9) than in C (3.5; 2.1–4.5) ( $P < 0.0001$ ). Ca/P ratio was significantly higher in PHPT than in C. ROC curves analyses identified a cutoff of 3.5 for both Ca/P ratio and Ca/P ratio obtained by using albumin corrected-Ca. The sensitivity and specificity were 86 and 87%, respectively for Ca/P ratio and 89 and 93%, respectively for corrected Ca/P ratio ( $P < 0.0001$ ). The diagnostic value of Ca/P ratio performed better than PTH and Ca used alone or in combination.

#### Conclusions

Ca/P ratio is a valuable highly sensitive, highly specific tool for the diagnosis of PHPT. Since Ca/P is simple to obtain, easily accessible in every clinical and lab setting worldwide, and inexpensive even when used in large sample size of patients, this diagnostic tool could be useful for screening PHPT, especially in patients accessing emergency rooms or in the general practitioner setting.

DOI: 10.1530/endoabs.41.EP146

## EP147

### Vitamin D status in infants during the first 9 months of age and its effect on growth and other biochemical markers: a prospective cohort study

Manish Gutch<sup>1</sup>, Uday Mandal<sup>2</sup> & Sukriti Kumar<sup>1</sup>

<sup>1</sup>King George Medical College, Lucknow, India; <sup>2</sup>LLRM Medical College, Meerut, India.

#### Background

We planned this prospective cohort study in term newborn babies, with the objective to determine the incidence of vitamin D deficiency in infancy and to determine the level of vitamin D which triggers the physiological axis of the body so as to differentiate truly deficient from sufficient vitamin D status.

#### Methods

96 participants at birth were enrolled and followed up till 9 months of age. Serum 25OHD was estimated in cord blood at birth and at 14 ± 1 weeks of life. 77 participants were followed up at 9 months for estimation of serum 25OHD, PTH, Alkaline phosphatase (ALP), calcium and phosphorus. Vitamin D deficiency was defined as serum 25OHD, PTH, Alkaline phosphatase (ALP), calcium and phosphorus. Vitamin D deficiency was defined as serum 25OHD.

#### Results

Serum 25OHD levels at 9 months of age (15.78 ± 8.97 ng/ml) were significantly increased in comparison to the level of 3 months of age (14.04 ± 7.10 ng/ml) and at birth (8.94 ± 2.24 ng/ml). At birth all the participants (77) were deficient in 25OHD levels. It was found that 16/94 (17%) and 19/77 (24.7%) participants at 3 and 9 months of age respectively became vitamin D sufficient without any vitamin D supplementation. There was a significant inverse correlation between serum 25OHD and PTH concentration ( $r = -0.522$ ,  $P < 0.001$ ) serum 25OHD and ALP ( $r = -.501$ ,  $P < 0.001$ ). It was found that reduction in serum vitamin D level to below 10.25 ng/ml results in surge of serum PTH.

#### Conclusion

Vitamin D deficiency is common from birth to 9 months of age but incidence decreases spontaneously even without supplementation. Also large number of babies may be falsely labelled as vitamin D deficient with currently followed cutoffs. So a new cutoff for vitamin D deficiency needs to be established for neonates and infants.

DOI: 10.1530/endoabs.41.EP147



## Author Index

- Aalaa, M GP104 & GP106  
 Aas, C OC8.4  
 Abad, A EP1118  
 Abaza, D EP515  
 Abbasoglu, O EP646  
 Abdallah, NB EP1042,  
 EP457 & GP101  
 abdalrahman, I EP523  
 AbdelRaof, Y EP190  
 Abdelsalam, M GP80  
 Abdelsalam, MM EP1004  
 AbdelWahab, E EP190  
 Abdul Salam Ahmed, M  
 EP759  
 Abellán, P EP1010  
 & EP1011  
 Åberg, D EP732  
 Aberer, F EP546  
 Abid, A EP531  
 Abid, M EP1007  
 Abitbol, J GP28  
 Abraham, P EP932  
 Abrosimov, A EP1130  
 Abs, R EP700  
 Abuin Fernandez, J EP474  
 Abusahmin, H EP431  
 Abushady, MM EP1004  
 Acerini, C EP14  
 Ach, K EP1059, EP179  
 & EP306  
 Achenbach, H GP14  
 Acikalın, M EP310  
 Acosta-Calero, C EP225  
 & EP93  
 Adamczewski, Z EP1023  
 Adamidou, F EP1121,  
 EP1154, EP30, EP44  
 & EP57  
 Adams, JE GP33  
 Adamska, A EP683 &  
 GP183  
 Adamski, J GP29  
 Adas, M EP968, EP1001  
 & EP1006  
 Adatepe, T OC3.5  
 Adaway, J GP178  
 Ademoglu, E EP1028,  
 EP1029, EP629  
 & EP788  
 Ademoglu, EN EP181,  
 EP524, EP696  
 & EP952  
 Adibi, H GP104  
 Adolf, C EP5  
 Adorini, L EP201 & GP56  
 Adorno, A EP1144  
 Affam, D EP187  
 Aflorei, ED EP854 & OC5.1  
 Afonso, EP334  
 Afzal, N EP228  
 Agapito, A EP643  
 & EP925  
 Agarwal, A EP1044  
 & EP1112  
 Agarwal, G EP1044  
 & EP1112  
 Agarwal, S EP84  
 Aggarwal, A EP343  
 Aggarwal, V EP343  
 Aghaei, M EP488  
 Aghajanova, Y EP549  
 & EP848  
 Aglony, M GP148  
 Agudo-Macazaga, M  
 GP199  
 Aguiar, NDMM EP392  
 Aguilar, M EP415  
 & EP861  
 Aguilar-Diosdado, M  
 EP558, EP801, EP832  
 & GP76  
 Aguilera-Tejero, E GP144  
 Aguirre Sanchez-Covisa,  
 M GP97  
 Ahbab, S EP161, EP456,  
 EP47 & EP478  
 Ahci, S EP1067  
 Ahmad, S EP363 & EP83  
 Ahmed, I GP80  
 Ahmed, M EP647  
 Ahmed Naseem, A EP228  
 & EP519  
 Ahmet Ay, S EP307,  
 EP320 & EP405  
 Ahn, C EP402 & EP962  
 Ahn, HJ EP198  
 Aho, L-S EP870  
 Ahtiainen, P EP138  
 Ai Kang, S EP402 & EP962  
 Aicha, B EP815  
 Aigelsreiter, A EP232  
 Aissa, A EP948  
 Aizic, A EP1090  
 Ajabnoor, G EP844B  
 Ajduk, M EP836  
 Ajmi, H GP84  
 Akalm, A EP357  
 & EP971  
 Akarsu, E GP166  
 Akay, E EP78  
 Akay, F OC6.1  
 Akbarov, Z EP537  
 Akbarova, Y EP400B  
 Akca, EP480  
 Åkerman, A-K GP167  
 Akdemir, NU EP178  
 Akin, F EP1078, EP252,  
 EP778, EP795  
 & EP821  
 Akkas, N EP105  
 Akkurt, A EP1111  
 Akkus, G EP18  
 Akli Ayoub, M OC10.2  
 Akram, M EP228, EP468,  
 EP519 & EP717  
 Aksyonova, E EP798  
 Aktar, MK EP660  
 Aktimur, R EP806  
 Akturk, M EP72  
 & EP173  
 Akulkina, L EP34  
 Akyay, OZ EP1030, EP105  
 & EP1101  
 Akyol, O EP178  
 Al Emadi, B EP647  
 Al Hindi, H EP647  
 Al Zaydi, M EP513  
 Alaarg, A EP195  
 Alacid, CM EP69  
 Alagoz, E EP1087  
 & EP380  
 Alam, MM EP311  
 Al-Amin, M GP84  
 Alaminos-Castillo, MA  
 EP807, EP811  
 & EP834  
 Alapi, T EP587  
 Albani, A EP736  
 Albert, L EP799 & GP13  
 Albu, SE EP134A  
 Alcaide, J EP803 & EP823  
 Alcaide-Torres, J EP168,  
 EP224, EP783 & OC7.1  
 Alcazar, V EP1118  
 Alcántara, C EP656  
 Aldahmani, KM EP166  
 Alekna, V EP112  
 Aleknaite, I EP112  
 Aleksandrov, Y EP399,  
 EP982 & EP983  
 Alevizaki, M EP874,  
 EP973 & GP237  
 Alevizaki, M  
 Alexaki, S EP1126  
 Alexander, E S1.1  
 Alexandra Hanzu, F  
 GP124  
 Alexandra, N EP268  
 Alexandraki, K EP618,  
 EP633 & GP23  
 Alexandru Niculescu, D  
 EP1066  
 Alexeev, D EP451  
 Alexescu, T EP828  
 Alexiadou, A EP1129  
 Alexiou, I EP436 & EP442  
 Alfredo Martinez, J OC12.3  
 Alhambra Exposito, MR  
 EP753  
 Alhambra-Exposito, MR  
 EP757  
 Al-Hashimi, A EP1128  
 Alhusuny, A EP513  
 & EP839  
 Ali Acar, E EP66  
 Ali Kasifoglu, M GP83  
 Ali, O EP523  
 Ali Raza Kazmi, S EP228  
 & EP519  
 Ali Tam, A EP1135,  
 GP209 & GP233  
 Alikasifoglu, M EP646  
 Alimehmeti, M EP1142  
 Alimova, K EP762  
 & EP763  
 Alio Lavín Gómez, B  
 EP979 & GP11  
 Alioglu, B EP524  
 Alissa, E EP242  
 Alkaabi, FM EP100  
 & EP166  
 Alkan, A EP1099 &  
 GP209  
 Alkan, G EP496  
 Alkebro, C GP167  
 Alla, L EP237  
 Allelein, S OC14.5  
 Allende, F GP148  
 Allendorf, I GP40  
 Aller, J EP1118  
 Allo, G EP107 & EP319  
 Alloisio, M GP111  
 Allolio, B GP116  
 Almaden, Y EP144  
 Almasri, MS EP1004  
 Almazrouei, RA EP100  
 & EP166  
 Almeida, L EP793  
 Almeida, R EP31  
 Almeida, RC EP346

- Ritzel, K OC7.3  
 Riva, E EP612 & EP865  
 Rivas-Rivas, M EP213  
 Rivezzi, M EP583  
 Riviere, L-D GP161  
 Rizk-Rabin, M GP116 & OC2.4  
 Rizou, A EP772  
 Rizov, C EP1048  
 Rizvi, SSR EP468 & EP717  
 Rjeb, O EP978  
 Roa, J EP789 & GP127  
 Roa Llamazares, C EP120  
 Robbins, R EP414  
 Robert, C EP6  
 Roberts, G EP657  
 Robledo, M EP247  
 Robles, J-P EP861  
 Roca-Rodríguez, M GP76  
 Rocha, DRTW EP392  
 Rocha, R EP334  
 Rochfort, K EP215  
 Rochira, V EP146 & EP718  
 Rodermund, L GP190  
 Rodondi, N S11.2  
 Rodríguez Berrocal, V EP1134  
 Rodríguez, IPD EP336  
 Rodríguez, NOD EP336  
 Rodríguez, O EP210  
 Rodríguez-Abreu, D GP216  
 Rodríguez-Cañete, A EP804  
 Rodríguez-Morata, A EP803  
 Rodríguez-Perálvarez, M GP131  
 Rodríguez-Ramos, C EP213  
 Rodrigues, A EP334  
 Rodrigues, D EP115, EP121, EP175, EP338, EP75, EP813, EP818 & GP92 & GP207  
 Rodrigues, E EP1104, EP722 & GP59  
 Rodrigues, F OC14.4  
 Rodrigues, J EP177  
 Rodrigues, M EP279  
 Rodrigues Marques, R GP203  
 Rodriguez, M GP144  
 Rodriguez, NC EP557  
 Rodriguez, R EP885  
 Rodriguez-Cañete, A EP807 & EP834  
 Rodriguez-Morata, A EP823  
 Rodriguez-Ortiz, ME GP144  
 Rodriguez-Pacheco, F EP807, EP811 & EP834  
 Rogatko, I EP751  
 Rohr, A GP130  
 Rojas, D GP145  
 Rojas Martelo, G EP1134  
 Rojas, R EP1037  
 Roji, AM EP117  
 Rojo, G EP557  
 Rolinski, J GP195  
 Rolo, F EP964  
 Roman, AC EP1102  
 Romaní, M EP743  
 Romanelli, F EP957  
 Romano, A GP172  
 Romero, J EP142  
 Romero, SG EP911  
 Romero-Gómez, M EP213  
 Romijn, J S7.1  
 Río-Moreno, Md GP131  
 Romualdi, D EP694  
 Ronchi, C EP15, OC1.1 & OC1.2  
 Ronchi, C GP116  
 Ronchi, CL OC2.3  
 Ronkainen, K EP203  
 Roomp, K GP7  
 Roque, C EP1005, EP258, EP635 & GP63  
 Rosa Alhambra-Expósito, M EP764  
 Rosario Acampado, L GP204  
 Rosciolesi, DV EP1102  
 Rose-John, S OC5.4  
 Rosendo, C GP76  
 Rosenfeld, RG EP845 & GP139  
 Rosmarin, M EP1012  
 Ross, IL EP56  
 Ross, R EP14 & OC5.3  
 Rossetto, R EP1094  
 Rossi, F GP136  
 Rossi, G EP883  
 Rostomyan, L EP889  
 Roszkowska-Purska, K EP593  
 Rotariu, D EP304  
 Rotermund, R EP899  
 Rouabhi, S EP671  
 Roughton, M GP153  
 Roumeliotaki, T EP136  
 Rousset, B GP235  
 Roussou, P EP890 & EP906  
 Rovira, E OC14.4  
 Roy, M EP84  
 Roy, P GP235  
 Rozhinskaia, L EP341  
 Rozhinskaya, L EP13, EP151, EP379, EP625 & EP99  
 Rozhynskaya, L EP596  
 Réti, Z EP1052  
 Rützi, S OC3.2  
 Ruano, MAD EP336  
 Rubin, B OC1.1  
 Rubini, C EP591  
 Rubino, M GP230  
 Rubio, E EP557  
 Rubio, O EP1010 & EP1011  
 Ruchala, M EP1022 & EP614  
 Ruchala, M EP1073, EP1100, EP202 & EP606  
 Rudakova, J EP483  
 Rudovich, N OC12.3  
 Rudser, K GP36  
 Rui Mascarenhas, M EP257  
 Ruiz de Azua, T EP1133  
 Ruiz, MCG EP168  
 Ruiz Ochoa, D EP979 & GP11  
 Ruiz-Gines, MA GP199  
 Ruiz-Gracia, T EP38 & EP754  
 Ruiz-Pino, F EP789 & GP127  
 Rump, LC EP5 & GP9  
 Rumpler, M EP546  
 Rungby, J EP25  
 Runkle de la Vega, I EP760  
 Runkle, I EP38 & EP754  
 Rurale, G GP171  
 Russo, D EP863  
 Rusu, C EP371  
 Ruthishauser, J GP155  
 Rutkowska, J EP19, EP416 & EP422  
 Rutz, S EP621  
 Ruza, I EP502  
 Ryan, M GP16  
 Rychlik, S GP208  
 Ryes, AG GP54  
 Ryhänen, EM EP138  
 Rylander, L EP741  
 Ryu, J EP1093  
 Rzepka, E EP280 & EP96  
 Saad, F EP204 & GP187  
 Saad, G EP179  
 Saad, H EP613  
 Saatov, T EP437  
 Saavedra, A EP1104, EP328, EP722, EP793, EP817 & GP59  
 Saavedra, A GP142  
 Saba, A EP137  
 Sabah, M EP1122  
 Sabino, F EP554  
 Sabino, T EP643 & EP925  
 Sacchetti, A D1.3  
 Sachs, S GP52  
 Šwider, G EP924  
 Świrska, J EP335  
 Sadiku, E EP505  
 Saed, M EP515  
 Saeedi, P EP839  
 Saeger, W OC9.5  
 Safi, A EP311  
 Saglam, B EP1032 & EP524  
 Saglam, F EP1021 & EP1050  
 Saglar, E EP405, EP409, EP420 & EP445  
 Sahin, AB EP1162 & EP36  
 Sahin, I EP826 & EP995  
 Sahin, M EP975  
 Sahin, T EP1009  
 Sahinoglu-Keskek, N GP89  
 Said, A EP309  
 Saida, F EP470, EP471, EP791 & EP815  
 Saidnazirkhanova, M EP709 & EP761  
 Saini, S EP666  
 Sainsbury, C EP411  
 Sakali, A-K EP782  
 Sala, E EP3  
 Salah, DB EP1007  
 Salam, R EP476  
 Salas, C GP66  
 Salas, RO GP112  
 Salavessa, J EP656  
 Salem, H GP82  
 Salem, LB EP186, EP325, EP692 & EP698  
 Salenave, S EP1057  
 Salenave, S GP163  
 Saler, T GP89  
 Salihoglu, M GP72  
 Salinas, CS EP398  
 Saltiki, K EP973 & GP237  
 Salvatierra, J GP112  
 Salvesen, H GP172